Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543567 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
NCT02543567 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 525 participants.
The verdict
NCT02543567, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen with the recently released batches of Ad26.ZEBOV and MVA-BN-Filo in terms of humoral immune response against the Ebola virus (EBOV) GP (glycoprotein) as measured by enzyme-linked immunosorbent assay (ELISA) at 21 days post boost.
Interventions
- BIOLOGICAL Ad26.ZEBOV 5*10^10 viral particles (vp)
- BIOLOGICAL Ad26.ZEBOV 2*10^10 (vp)
- BIOLOGICAL Ad26.ZEBOV 0.8*10^10 (vp)
- BIOLOGICAL MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]
- BIOLOGICAL MVA-BN-Filo 5*10^7 Inf. U.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2015-09-21 |
| Est. Completion | 2016-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02543567
The ClinicalTrials.gov registry entry for NCT02543567 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ad26.ZEBOV 5*10^10 viral particles (vp) is the first listed.
NCT02543567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02543567 about?
NCT02543567 is a clinical study titled "A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants". The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen with the recently released batches of Ad26.ZEBOV and MVA-BN-Filo in te...
What is the current status of trial NCT02543567?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2015-09-21. Estimated completion is 2016-11-29.
What interventions are being tested in trial NCT02543567?
The interventions under investigation include: Ad26.ZEBOV 5*10^10 viral particles (vp) (BIOLOGICAL), Ad26.ZEBOV 2*10^10 (vp) (BIOLOGICAL), Ad26.ZEBOV 0.8*10^10 (vp) (BIOLOGICAL), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] (BIOLOGICAL), MVA-BN-Filo 5*10^7 Inf. U. (BIOLOGICAL).
Who is sponsoring clinical trial NCT02543567?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.